Security
XORTX Therapeutics Inc. Common Shares · XRTX
XRTXNASDAQCommon stockCurrentCIK 1729214Updated Oct 9, 2026
XRTX price & chart
Loading TradingView…
NASDAQ:XRTX on TradingView ↗About the company
XORTX Therapeutics is a late clinical-stage biotechnology company focused on identifying, developing and potentially commercializing therapies to treat diseases modulated by aberrant purine and uric acid metabolism in indications such as gout, autosomal dominant polycystic kidney disease (“ADPKD”) an orphan (rare) disease and larger, more prevalent type 2 diabetic nephropathy (“T2DN”) as well as acute kidney injury (“AKI”) associated with respiratory virus infection. In addition, XORTX has expanded interest to include anti-fibrotic medicine in kidney disease.
In the news
No coverage from other publishers is available.
Seeking Alpha
XORTX Therapeutics appoints Mika Grasso as co‑CEO ↗
XORTX Therapeutics regains Nasdaq compliance ↗
SEC disclosures
XORTX Therapeutics Inc. files final prospectus (424B4) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2021 · CADcash flow · annual statements
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossCAD | -1,652,282Source | -1,284,602Source |
| Additional Financial Items | ||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableCAD | -37,188Source | — |
| AdjustmentsForSharebasedPaymentsCAD | 499,158Source | 293,443Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -325,741Source | 1,201Source |
| GeneralAndAdministrativeExpenseCAD | 176,099Source | 9,516Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesCAD | 39,809Source | 14,350Source |
income statement · annual statements
| Line item | FY 2021 | FY 2020 |
|---|---|---|
| Additional Financial Items | ||
| AdministrativeExpenseCAD | 4,198Source | — |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossCAD | 6,119,000Source | — |
| DepreciationAndAmortisationExpenseCAD | 17,882Source | 20,439Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesCAD | 499,158Source | 293,443Source |
| GeneralAndAdministrativeExpenseCAD | 176,099Source | 9,516Source |
| PostemploymentBenefitExpenseDefinedContributionPlansCAD | 380,000Source | 192,000Source |
| ProfessionalFeesExpenseCAD | 272,943Source | 162,580Source |
| ProfitLossBeforeTaxCAD | -3,649,523Source | -1,395,993Source |
| ResearchAndDevelopmentExpenseCAD | 853,124Source | 277,455Source |
Offerings
Registration 333-290512
- Gross proceeds
- 5000000.0
- Net proceeds
- 4800000.0
- Deal price
- 1.88
- Shares
- 2659574
- Offering price
- $1.88
- Ticker
- XRTX
Underwriters: May 13, 2026, E.F. Hutton & Co.
Filing attachments
xortxex99-1.htm · 6-K · 2026-09-09
Exhibit 99.1 September 8, 2026 XORTX Re-Engages Investor Relations Program CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture Exchange, XORTX has re-engaged IR Agency LLC pursuant to a consulting agreement providing for investor relations and marketing services on substantially the same terms previously disclosed by the Company in i…
Read attachment ↗xortxex99-2.htm · 6-K · 2026-09-09
Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company XORTX Therapeutics Inc. (“XORTX” or the “Company”) 3710 - 33rd Street NW Calgary, Alberta T2L 2M1 Item 2: Date of Material Change September 2, 2026 Item 3: News Release The news release was disseminated on September 8, 2026, through GlobeNewswire and filed on SEDAR+. Item 4: Summary of Material Change On September 2, 2026, following completion of its previously announced voluntary delisting from the…
Read attachment ↗xortxex99-1.htm · 6-K · 2026-09-04
Exhibit 99.1 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to XORTX Therapeutics Inc (XRTX) (“you,” “Client” or “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which Company engages Consultant to provide such services. Consulting Services. (a) Commencing on 9/3/2026, Consultant will provide marketing and advertising services …
Read attachment ↗tm265452d5_ex4-1.htm · POS AM · 2026-04-22
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES XORTX THERAPEUTICS INC. Warrant Shares: [*] Initial Exercise Date: [*], 2026 THIS PRE-FUNDED COMMON SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [*] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in …
Read attachment ↗tmb-20251231xex4d10.htm · 20-F · 2026-03-20
Exhibit 4.10 Execution Copy SUMMARY OF TERMS FOR AN ASSET ACQUISITION BETWEEN Vectus Biosystems Limited (ASX: VBS) AND XORTX Therapeutics Inc. (Nasdaq: XRTX and TSXV: XRTX) This Summary of Terms (the “Term Sheet”) sets forth the understanding with regard to a proposed asset acquisition (the “Asset Acquisition”) between XORTX Therapeutics Inc. (the “Buyer”) and Vectus Biosystems Limited (the “Seller”), whereby the Buyer will acquire the Assets (as defined below) in exchange for common sha…
Read attachment ↗tmb-20251231xex4d11.htm · 20-F · 2026-03-20
Exhibit 4.11 EXTENSION AGREEMENT This extension agreement (this “Agreement”) is dated the 13th day of January, 2026 (the “Effective Date”). AMONG: VECTUS BIOSYSTEMS LIMITED (“Vectus”) - and - XORTX THERAPEUTICS INC. (the “Company”) (Collectively, the “Parties”, and as to each, a “Party”) WHEREAS: On October 15, 2025 the Parties entered into a term sheet (the “Term Sheet”) regarding the Company’s proposed purchase of, inter alia, Vectus’ VB4-P5 Renal Antifibrotic Therapeutic Treatmen…
Read attachment ↗